Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data

Condition(s) studied

Investigational drug(s) / intervention(s)

Heart monitoring tools (data revision): data collected by the devices will be reviewed by the treating physician in the intervention group

Control (Standard treatment): Patients in the control group will be monitored but the information will not be available for the clinicians nor the artificial intelligence recommendations

Study summary

The goal of this study is to create a digital platform for managing patients with chronic heart failure, those with long-term ventricular assistance, or heart transplant recipients. This platform aims to help doctors make clinical decisions and change treatments based on continuous monitoring and the collection of medical, clinical, physiological, behavioral, psychosocial, and real-world data from these patients.

The ultimate goal is to reduce mortality and hospitalization rates for this group of patients while improving their quality of life, safety, and well-being.

To do this, participants will be divided into two groups:

* Intervention Group: The data collected by the platform will be available to their treating doctors.
* Control Group: Doctors will not have access to the data.

All participating patients will receive a set of devices and sensors to collect data such as vital signs, physical activity, sleep quality, psychological and nutritional status, and environmental data. All this information will be gathered through a mobile app designed for the study.

The follow-up will last for 18 months, during which there will be 4 in-person medical visits (spaced 4 months apart). Participation in the study won't affect patients' scheduled medical visits related to their illness or their usual treatment.

Eligibility

Primary outcome measure(s)

• Difference in days lost due to unplanned cardiovascular hospitalizations or all-cause death between groups — From the enrollment to the end of the follow up (18 months)
  Comparison of days lost due to unplanned cardiovascular hospitalizations or all-cause death between groups
• Differences in the rates of occurrence of death or unplanned hospitalization/ambulatory administration of intravenous (iv) diuretics, iv antibiotics or iv steroids — From the enrollment to the end of the follow up (18 months)
  Comparison of the rates of the occurrence of death or unplanned hospitalization/ambulatory administration of intravenous (iv) diuretics, iv antibiotics or iv steroids between groups

Trial sites (6)